Select Page

News

Tracking the latest developments from across the health sciences industry
Home 9 NewsPage 90
Covid Potential for Brain Damage, According to Scientists
Covid Potential for Brain Damage, According to Scientists

A study conducted by researchers at University College London (UCL) reported 43 cases of patients diagnosed with Covid experiencing temporary brain damage. The scientists warned that new evidence suggests potential issues of severe neurological complications, like...

Early Potential in Human Trials for Covid Vaccine
Early Potential in Human Trials for Covid Vaccine

BioNTech, and Pfizer have partnered to produce one of the 17 Covid vaccines currently in development. The vaccine has shown promising early-stage human trials among 24 participants, alongside other pharmaceutical companies like Moderna, Inovio Pharmaceuticals,...

Gilead Sets Price for Covid Treatment Remdesivir
Gilead Sets Price for Covid Treatment Remdesivir

Gilead Sciences, the biotech company based out of California that created one of the first original treatments for Covid, has set the price for remdesivir between $2,340 and $3,120 for a typical course treatment. While remdesivir has still yet to prove to reduce...

ABOUT US

CSOFT Health Sciences has over 15 years of experience providing end-to-end translation and localization solutions for all stages of the product life cycle, from pre-clinical to post-launch. We also specialize in China market access consulting services, Asian regulatory and eCTD submissions. Our operation is compliant with ISO 17100 and certified by BSI in ISO 9001:2015 and ISO 13485:2016, providing customized solutions to meet the rigorous regulatory requirements in global submission. For more information, please visit: www.csoftintl.com